secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001493152-24-044932
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics Q3 net loss widens to $5.1M; FDA clears NeuroNova IND
----------------------------------------------------------------------------

- Net loss of $5.1M ($0.65/share) vs. $2.0M ($1.41/share) in Q3 2023.
- R&D expenses $2.2M, down from $3.3M; G&A $3.1M, down from $4.0M.
- Cash and restricted cash $2.1M as of Sept 30, 2024, unchanged from Dec 31, 2023.
- FDA cleared IND for NeuroNova (CLD-101) Phase 1b/2 trial in high-grade glioma; trial expected early 2025.
- Raised $2M in registered direct offering and private placement in October.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224044932/0001493152-24-044932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224044932/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer